|
|
|
|
| LEADER |
01973nam a2200229 u 4500 |
| 001 |
EB002191720 |
| 003 |
EBX01000000000000001329185 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
240105 r ||| eng |
| 100 |
1 |
|
|a Mackey, Katherine
|
| 245 |
0 |
0 |
|a Antibody response following SARS-CoV-2 infection and implications for immunity
|h Elektronische Ressource
|b a rapid living review
|c Katherine Mackey, Irina Arkhipova-Jenkins, Charlotte Armstrong, Emily Gean, Johanna Anderson, Robin A. Paynter, Mark Helfand
|
| 260 |
|
|
|a [Rockville, Md.]
|b Agency for Healthcare Research and Quality
|c 2021, March 2021
|
| 300 |
|
|
|a 1 PDF file (108 pages)
|b illustrations
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 710 |
2 |
|
|a United States
|b Agency for Healthcare Research and Quality
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a Rapid evidence product
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK569148
|3 Volltext
|
| 082 |
0 |
|
|a 610
|
| 520 |
|
|
|a The aims of this rapid systematic review are to synthesize evidence on the prevalence, levels, and durability of the antibody response to SARS-CoV-2 infection among adults and how antibodies correlate with protective immunity. Given the rapidly evolving evidence within this field, the Agency for Healthcare Research and Quality's Evidence-based Practice Center (AHRQ EPC) Program will maintain this report as a living review with planned ongoing literature surveillance and critical appraisal. We will provide regular report updates as additional evidence becomes available, modifying the scope of the review as new directions in SARS-CoV-2 immunity research emerge. This review was conducted in coordination with the American College of Physicians (ACP) as part of AHRQ's standing work to provide health professional organizations and systems with evidence reviews to support the development of clinical guidance for their clinician members
|